Alpha, Omicron: Why?

Over the past week, global financial markets have been roiled by the discovery of the “Omicron” COVID-19 mutation. It’s far too soon to know how much this new variant will impact the world’s economy—but its discovery suggests an interesting thought experiment in, of all things, corporate governance.

The experiment is this: suppose Omicron turns out to be very dangerous and leads to a series of draconian economic shutdowns. Suppose further that a pharmaceutical manufacturer “X” comes up with a miracle cure—a vaccine that’s easy to administer and 100% effective. 

You can now read the full whitepaper at the link below